Location History:
- Singapore, SG (2019)
- Brookline, MA (US) (2018 - 2022)
Company Filing History:
Years Active: 2018-2022
Title: **Innovative Contributions of Inventor Yvonne Tay**
Introduction
Yvonne Tay is an accomplished inventor based in Brookline, MA, with a remarkable portfolio of three patents. Her work primarily focuses on innovative solutions in the field of cancer treatment through the development of micro-RNA inhibitors. With her expertise and dedication, Tay has made significant contributions to medical research and therapeutic advancements.
Latest Patents
Yvonne Tay's latest patents include groundbreaking inventions aimed at treating and preventing cancer. One of her notable inventions is related to micro-RNA inhibitors and their uses in disease. This invention addresses cancer treatment by administering agents that inhibit the activity of microRNAs, which modulate tumor suppressor genes, including PTEN, p53, and INPP4B, among others. The inhibitors can consist of oligonucleotides that are at least partially complementary to these miRNAs. Some embodiments feature chemically modified oligonucleotides, such as locked nucleic acids (LNAs).
Another significant patent involves compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancers. Tay has introduced novel mIR-330 agents along with their methods of use, which provide effective strategies for treating MYC-associated malignancies.
Career Highlights
Yvonne Tay is affiliated with Beth Israel Deaconess Medical Center, Inc., where she contributes her expertise in cancer research and innovation. Her work in developing novel therapeutic agents has positioned her as a leading figure in the medical field, particularly in oncology treatments.
Collaborations
Throughout her career, Yvonne has collaborated with esteemed colleagues such as Pier Paolo Pandolfi and Laura Poliseno. These partnerships have facilitated groundbreaking research, further enhancing the quality and impact of their collective work in cancer treatment.
Conclusion
Yvonne Tay's inventive contributions showcase her commitment to advancing cancer therapy through innovative applications of micro-RNA inhibitors. With valuable collaborations and her role at Beth Israel Deaconess Medical Center, she continues to play a pivotal role in transforming cancer treatment methodologies, ultimately benefiting patients and the broader medical community.